ArticleJournal of immunology (Baltimore, Md. : 1950)2010
A cell-impermeable cyclosporine A derivative reduces pathology in a mouse model of allergic lung inflammation.
Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 53 citations in OpenAlex.
- Human Cyclophilins-An Emerging Class of Drug Targets.Medicinal research reviews · 2026Review
- Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability.European journal of medicinal chemistry · 2023Article
- Exploratory Investigation of the Plasma Proteome Associated with the Endotheliopathy of Trauma.International journal of molecular sciences · 2022Article
- Current update on theranostic roles of cyclophilin A in kidney diseases.Theranostics · 2022Review
- Secreted Extracellular Cyclophilin A Is a Novel Mediator of Ventilator-induced Lung Injury.American journal of respiratory and critical care medicine · 2021Article
- The contribution of cyclophilin A to immune-mediated central nervous system inflammation.Journal of neuroimmunology · 2020Article
- Extracellular and Intracellular Cyclophilin A, Native and Post-Translationally Modified, Show Diverse and Specific Pathological Roles in Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2018Review
- Pharmacological targeting of allergen-specific T lymphocytes.Immunology letters · 2017Review
- Extracellular Cyclophilin A, Especially Acetylated, Causes Pulmonary Hypertension by Stimulating Endothelial Apoptosis, Redox Stress, and Inflammation.Arteriosclerosis, thrombosis, and vascular biology · 2017Article
- Targeting Extracellular Cyclophilin A Reduces Neuroinflammation and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017Article
- Extracellular cyclophilins in health and disease.Biochimica et biophysica acta · 2015Review
- Targeting Extracellular Cyclophilins Ameliorates Disease Progression in Experimental Biliary Atresia.Molecular medicine (Cambridge, Mass.) · 2015Article
- Inhibition of extracellular cyclophilins with cyclosporine analog and development of atherosclerosis in apolipoprotein E-deficient mice.The Journal of pharmacology and experimental therapeutics · 2015Article
- Article
- Cyclophilin A: a key player for human disease.Cell death & disease · 2013Review
- VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice.PloS one · 2013Article
- Exposure to particulate hexavalent chromium exacerbates allergic asthma pathology.Toxicology and applied pharmacology · 2012Article
- Article
- Extracellular cyclophilin levels associate with parameters of asthma in phenotypic clusters.The Journal of asthma : official journal of the Association for the Care of Asthma · 2011Article
- Blocking cyclophilins in the chronic phase of asthma reduces the persistence of leukocytes and disease reactivation.American journal of respiratory cell and molecular biology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Although the main regulators of leukocyte trafficking are chemokines, another family of chemotactic agents is cyclophilins. Intracellular cyclophilins function as peptidyl-prolyl cis-trans isomerases and are targets of the immunosuppressive drug cyclosporine A (CsA). Cyclophilins can also be secreted in response to stress factors, with elevated levels of extracellular cyclophilins detected in several inflammatory diseases. Extracellular cyclophilins are known to have potent chemotactic properties, suggesting that they might contribute to inflammatory responses by recruiting leukocytes into tissues. The objective of the present study was to determine the impact of blocking cyclophilin activity using a cell-impermeable derivative of CsA to specifically target extracellular pools of cyclophilins. In this study, we show that treatment with this compound in a mouse model of allergic lung inflammation demonstrates up to 80% reduction in inflammation, directly inhibits the recruitment of Ag-specific CD4(+) T cells, and works equally well when delivered at 100-fold lower doses directly to the airways. Our findings suggest that cell-impermeable analogs of CsA can effectively reduce inflammatory responses by targeting leukocyte recruitment mediated by extracellular cyclophilins. Specifically blocking the extracellular functions of cyclophilins may provide an approach for inhibiting the recruitment of one of the principal immune regulators of allergic lung inflammation, Ag-specific CD4(+) T cells, into inflamed airways and lungs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.